Sensitivity of DHL cell lines to OR-2100 when used as a single agent or as combination therapy. (A) RC cells, DOHH2 cells, OCI-Ly18 cells, SU-DHL-10 cells, WSU-DLCL2 cells, and SU-DHL-6 cells were treated with HMAs (AZA, DAC, or OR-2100) for 72 hours, followed by cell viability assays. (B) The proportion of apoptotic cells in SU-DHL-6, SU-DHL-10, RC, and OCI-Ly18 cells after 72 hours of treatment with vehicle, 500 nM AZA, or OR-2100. The combined effect of OR-2100 and doxorubicin (C) or vincristine (D) in RC cells and SU-DHL-6 (calculated by SynergyFinder Plus). The combination of OR-2100 and doxorubicin has an additive effect against both RC cells and SU-DHL-6 cells. The combination of OR-2100 and vincristine has an additive effect against RC cells and SU-DHL-6 cells. mut, mutation; ns, not significant; wt, wild type.
Figure 1.

Sensitivity of DHL cell lines to OR-2100 when used as a single agent or as combination therapy. (A) RC cells, DOHH2 cells, OCI-Ly18 cells, SU-DHL-10 cells, WSU-DLCL2 cells, and SU-DHL-6 cells were treated with HMAs (AZA, DAC, or OR-2100) for 72 hours, followed by cell viability assays. (B) The proportion of apoptotic cells in SU-DHL-6, SU-DHL-10, RC, and OCI-Ly18 cells after 72 hours of treatment with vehicle, 500 nM AZA, or OR-2100. The combined effect of OR-2100 and doxorubicin (C) or vincristine (D) in RC cells and SU-DHL-6 (calculated by SynergyFinder Plus). The combination of OR-2100 and doxorubicin has an additive effect against both RC cells and SU-DHL-6 cells. The combination of OR-2100 and vincristine has an additive effect against RC cells and SU-DHL-6 cells. mut, mutation; ns, not significant; wt, wild type.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal